Cargando…
Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
Bispecific antibodies (BsAbs) are designed to recognize and bind to two different antigens or epitopes. In the last few decades, BsAbs have been developed within the context of cancer therapies and in particular for the treatment of hematologic B-cell malignancies. To date, more than one hundred dif...
Autores principales: | Lejeune, Margaux, Köse, Murat Cem, Duray, Elodie, Einsele, Hermann, Beguin, Yves, Caers, Jo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221185/ https://www.ncbi.nlm.nih.gov/pubmed/32457743 http://dx.doi.org/10.3389/fimmu.2020.00762 |
Ejemplares similares
-
Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma
por: Lejeune, Margaux, et al.
Publicado: (2021) -
Integrative Analysis of Proteomics and Transcriptomics Reveals Endothelin Receptor B as Novel Single Target and Identifies New Combinatorial Targets for Multiple Myeloma
por: Lejeune, Margaux, et al.
Publicado: (2023) -
Radiotheranostic Agents in Hematological Malignancies
por: Caers, Jo, et al.
Publicado: (2022) -
A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma
por: Duray, Elodie, et al.
Publicado: (2021) -
Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in Osteoclasts
por: Muller, Joséphine, et al.
Publicado: (2019)